Condition:   Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: ranibizumab
Sponsors:   Johns Hopkins University;   Juvenile Diabetes Research Foundation
Recruiting - verified February 2010

Conditions:   Arrhythmia;   Heart Failure
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Conditions:   Arrhythmia;   Bradycardia
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Conditions:   Arrhythmia;   Heart Failure
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Condition:   Abdominal Aortic Aneurysm
Interventions:   Device: PEVAR (ProGlide closure);   Device: SEVAR (IntuiTrak);   Device: PEVAR (Prostar XL closure)
Sponsors:   Endologix;   Abbott Vascular
Not yet recruiting - verified February 2010

Condition:   Influenza
Interventions:   Drug: Favipiravir;   Drug: Favipiravir;   Drug: Placebo comparator
Sponsor:   Toyama Chemical Co., Ltd.
Recruiting - verified March 2010

Condition:   Glaucoma
Interventions:   Drug: AR-12286 0.5% ophthalmic solution;   Drug: AR-12286 0.25% Ophthalmic solution;   Drug: Latanoprost ophthalmic solution
Sponsor:   Aerie Pharmaceuticals
Recruiting - verified March 2010

Condition:   Hypertriglyceridemia
Interventions:   Drug: AMR101 (ethyl icosapentate);   Drug: AMR101 (ethyl icosapentate);   Drug: Placebo
Sponsor:   Amarin Pharma Inc.
Recruiting - verified February 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: aclidinium bromide;   Drug: aclidinium bromide
Sponsors:   Forest Laboratories;   Almirall, S.A.
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Graft-Versus-Host Disease;   Immune System Disorders
Interventions:   Drug: Mycophenolate Mofetil;   Drug: Placebo
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010

Conditions:   Acute Coronary Syndrome;   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Coronary Artery Disease
Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
Recruiting - verified March 2010

Condition:   Arrhythmia Prophylaxis
Interventions:   Drug: Celivarone (SSR149744);   Drug: amiodarone;   Drug: placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified February 2010

Condition:   Rhinosinusitis
Intervention:   Device: FinESS Sinus Treatment
Sponsor:   Entellus Medical, Inc.
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions:   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Coronary Artery Disease
Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Hot Flashes;   Menopausal Symptoms;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: flaxseed;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Hepatitis C
Intervention:   Drug: Infergen with or without ribavirin
Sponsor:   Three Rivers Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Factor XIII Deficiency
Intervention:   Biological: FXIII Concentrate Human
Sponsor:   CSL Behring
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Dimebon
Sponsors:   Pfizer;   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions:   Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
Sponsors:   Regeneron Pharmaceuticals;   Bayer
Recruiting - verified February 2010

Condition:   Carcinoma of Unknown Primary
Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Low Back Pain
Interventions:   Biological: Tanezumab 20 mg;   Biological: Tanezumab 10 mg
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Placebo;   Drug: GW856553;   Drug: GW856553
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: LY2062430;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Herpes Zoster;   Shingles
Interventions:   Drug: valacyclovir;   Drug: FV-100;   Drug: FV-100;   Drug: Valacyclovir placebo;   Drug: FV-100 placebo
Sponsor:   Inhibitex
Recruiting - verified February 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: dasatinib;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: capecitabine;   Drug: sunitinib malate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab [RoActemra];   Drug: tocilizumab [RoActemra];   Drug: Nonbiologic DMARDs of investigator's choice
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: dexamethasone;   Drug: gabapentin;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Low Back Pain
Interventions:   Biological: Tanezumab 20 mg IV;   Drug: Placebo for naproxen;   Biological: Tanezumab 10 mg IV;   Drug: Placebo for naproxen;   Biological: Tanezumab 5 mg IV;   Drug: Placebo for naproxen;   Biological: Placebo for tanezumab;   Drug: Naproxen;   Biological: Placebo for tanezumab;   Drug: Placebo for naproxen
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Coronary Artery Bypass;   Myocardial Infarction;   Ventricular Dysfunction, Left;   Stroke;   Cardiopulmonary Bypass
Interventions:   Drug: Acadesine;   Drug: Normal Saline
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Heart Failure
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment
Sponsors:   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Chemotherapeutic Agent Toxicity;   Neurotoxicity;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: paclitaxel;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: assessment of therapy complications
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Alogliptin and metformin;   Drug: Alogliptin and metformin;   Drug: Glipizide and metformin
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Arthritis;   Osteoarthritis
Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Cetuximab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Cisplatin
Sponsors:   Accelerated Community Oncology Research Network;   ImClone LLC;   Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010

Condition:   Osteoarthritis
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Osteoarthritis;   Arthritis
Interventions:   Drug: NSAID;   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab;   Drug: NSAID;   Biological: tanezumab;   Drug: NSAID
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: pemetrexed disodium;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: Placebo
Sponsors:   Merck;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cladribine;   Drug: temsirolimus;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Phenylketonuria;   Hyperphenylalaninaemia
Intervention:   Drug: Sapropterin Dihydrochloride
Sponsor:   BioMarin Pharmaceutical
Recruiting - verified January 2010

Condition:   Lung Cancer
Interventions:   Other: clinical observation;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: rhGAD65;   Drug: rhGAD65;   Drug: Placebo
Sponsor:   Diamyd Therapeutics AB
Recruiting - verified March 2010

Conditions:   Arthritis;   Osteoarthritis;   Osteoarthritis, Hip
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: temsirolimus
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: cisplatin;   Drug: vandetanib;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: American ginseng;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Relapsed Follicular Lymphoma
Interventions:   Drug: VELCADE, rituximab, cyclophosphamide, prednisone, and Doxorubicin;   Drug: VELCADE, rituximab, cyclophosphamide, and prednisone
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Conditions:   Diabetic Retinopathy;   Diabetes Complications
Interventions:   Procedure: Laser Treatment;   Drug: PF-04523655 high;   Drug: PF-04523655 middle;   Drug: PF-04523655 low
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: sunitinib malate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Fatigue;   Psychosocial Effects of Cancer and Its Treatment;   Sleep Disorders
Interventions:   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Australian New Zealand Breast Cancer Trials Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: midostaurin;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Cystic Fibrosis
Interventions:   Drug: inhaled mannitol;   Drug: Placebo comparator
Sponsors:   Pharmaxis;   ethica Clinical Research Inc.
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
Interventions:   Drug: Placebo;   Biological: Romiplostim
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Hypoactive Sexual Desire Disorder
Interventions:   Drug: testosterone gel;   Drug: placebo gel
Sponsor:   BioSante Pharmaceuticals
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: letrozole;   Drug: tamoxifen citrate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: panitumumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: everolimus;   Drug: temozolomide;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: adjuvant therapy;   Procedure: computed tomography;   Procedure: single photon emission computed tomography;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: fludeoxyglucose F 18;   Radiation: intensity-modulated radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: panitumumab;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: docetaxel;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin;   Other: clinical observation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Neurotoxicity;   Pain;   Peripheral Neuropathy;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Invasive Breast Cancer
Interventions:   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: trastuzumab;   Drug: lapatinib
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Heart Decompensation
Interventions:   Drug: Placebo;   Drug: Nesiritide
Sponsor:   Scios, Inc.
Recruiting - verified February 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: AMG 706;   Drug: placebo
Sponsors:   Amgen;   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: denileukin diftitox;   Biological: rituximab;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cancer Survivor;   Sexual Dysfunction and Infertility;   Sexuality and Reproductive Issues;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Dietary Supplement: L-arginine/Korean ginseng/ Gingko biloba/damiana-based supplement;   Other: placebo
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Ototoxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: pemetrexed disodium;   Drug: sorafenib tosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Type 1 Diabetes Mellitus
Intervention:   Drug: Otelixizumab
Sponsors:   Tolerx Inc.;   Juvenile Diabetes Research Foundation
Recruiting - verified June 2009

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: cognitive assessment;   Procedure: diffusion tensor imaging;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Small Intestine Cancer
Interventions:   Drug: capecitabine;   Drug: irinotecan hydrochloride;   Drug: oxaliplatin
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions:   Drug: motesanib diphosphate;   Drug: octreotide acetate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Procedure: computed tomography
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: dasatinib;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Metastatic Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFIRI - Panitumumab;   Drug: FOLFIRI - Bevacizumab
Sponsor:   Amgen
Recruiting - verified February 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: conventional surgery
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Lung Cancer;   Metastatic Cancer;   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   American College of Surgeons;   Eastern Cooperative Oncology Group;   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Cognitive/Functional Effects;   Fatigue;   Metastatic Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity
Interventions:   Drug: donepezil hydrochloride;   Other: placebo
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Kidney Cancer
Intervention:   Biological: aflibercept
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: entinostat
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Conditions:   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Osteoporosis;   Ovarian Cancer
Interventions:   Drug: zoledronic acid;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: paclitaxel poliglumex;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: bortezomib;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pneumonia, Staphylococcal
Interventions:   Drug: linezolid;   Drug: vancomycin
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: zoledronic acid;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: alemtuzumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: pentostatin
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Menopausal Symptoms;   Sexual Dysfunction and Infertility
Interventions:   Drug: cyclophosphamide;   Drug: goserelin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   International Breast Cancer Study Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: imatinib mesylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Melanoma (Skin)
Intervention:   Biological: PEG-interferon alfa-2b
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: therapeutic immune globulin;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Children's Oncology Group
Recruiting - verified March 2010